High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma.

Xiaoyan Yue; Linlin Huang; Yang Yang; Yi Zhao; Donghua HE; Xiaoyan Han; Gaofeng Zheng; Yi LI; Enfan Zhang; Zhen Cai; Xin Huang; Jingsong HE

Return

High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma.

Author: Xiaoyan YUE ¹ ; Linlin HUANG ¹ ; Yang YANG ¹ ; Yi ZHAO ¹ ; Donghua HE ¹ ; Xiaoyan HAN ¹ ; Gaofeng ZHENG ¹ ; Yi LI ¹ ; Enfan ZHANG ¹ ; Zhen CAI ¹ ; Xin HUANG ² ; Jingsong HE ³
Author Information

1. Bone Marrow Transplantation Center, Department of Hematology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
2. Institute of Hematology, Department of Hematology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
3. Bone Marrow Transplantation Center, Department of Hematology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China. hejingsong@zju.edu.cn.
Publication Type:Journal Article
MeSH: Adult; Humans; Cytokines; Disease Progression; Interleukin-10; Interleukin-6/metabolism*; Multiple Myeloma/drug therapy*; Tumor Microenvironment; Vascular Endothelial Growth Factor A
From: Journal of Zhejiang University. Science. B 2022;23(11):968-974
CountryChina
Language:English
Abstract: Multiple myeloma (MM) is a common malignant hematological tumor in adults, which is characterized by clonal malignant proliferation of plasma cells in the bone marrow and secretion of a large number of abnormal monoclonal immunoglobulins (M protein), leading to bone destruction, hypercalcemia, anemia, and renal insufficiency (Alexandrakis et al., 2015; Yang et al., 2018). Since a large number of new drugs, represented by proteasome inhibitors and immunomodulators, have been successfully used to treat MM, treatment efficacy and survival of patients have been significantly improved. However, due to the high heterogeneity of this disease, patients have responded differently to treatments with these new drugs (Palumbo and Anderson, 2011; Wang et al., 2016; Huang et al., 2020). Growth and survival of MM cells depend on the bone marrow microenvironment, especially numerous inflammatory cytokines secreted by myeloma cells and bone marrow stromal cells, such as vascular endothelial growth factor (VEGF), interleukin (IL)‍-6, transforming growth factor-‍β (TGF‍‍-‍‍β), and IL-10. These cytokines can promote the growth of myeloma cells, induce angiogenesis, and inhibit antitumor immunity, and are often linked to patient prognosis (Kumar et al., 2017). In this era of new drugs, the prognostic values of the serum levels of these cytokines in MM need further evaluation.